Surg-04. Cranial Bone Defects in Patients Treated With Ttfields: a Case Series
Year: 2017
Type: conference-abstract
Abstract: Glioblastoma multiforme (GBM) is the most abundant primary brain tumor with a devastating prognosis. Treatment of newly diagnosed GBM is generally based on maximal safe resection and subsequent concomitant chemoradiation followed by adjuvant temozolomide (TMZ). Tumor-treating-fields (TTFields) are a new treatment modality added to the temozolomide maintenance with proven efficacy in a large clinical trial. The therapy is based on anti-mitotic effects of alternating electric fields applied locally through so called transducer arrays being directly attached to the scalp. Patients with cranial bone defects, e.g. missing bone, were excluded from the clinical trial with TTFields and clinical experience regarding safety and feasibility is missing. We here report on cases with cranial defect on TTFields therapy. CASES: We observed four patients with recurrent GBM and missing cranial bone (female=1, male=3) at four different centers in Germany. The median age when starting the therapy was 55 years (range 51 - 69 years). All patients received first-line treatment at best clinical practice and experienced progressive disease. Craniectomy was indicated due to different reasons like inflammation or wound healing deficit. Thereafter, treatment with TTFields started in these patients at first and later recurrence. There were no severe adverse events observed in this population. The median monthly compliance was 83 % and with a range of 78 – 84 % compliance, all patients exceeded 75 % as suggested by study data to enable most efficient therapy. This multicentric and retrospective case series describes patients who were treated with TTFields despite a cranial bone defect. All patients were compliant to the therapy and there were no severe or additional side effects observed. Our observation provides first evidence that this setting is feasible and safe. Additional studies are warranted to increase clinical evidence for the safe use of TTFields in patients with cranial bone defects.
Source: Neuro-Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2767401824
